Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan P van Meerbeeck

Showing results (21-30 of 190) with videos related to

Pageof 19
Sort By:
Current Opinion in Oncology|February 3, 2007
Neoadjuvant chemotherapy in the treatment of nonsmall-cell lung cancerRebecca De Pauw, Jan P van Meerbeeck
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2013
Surgery in mesothelioma--where do we go after MARS?Birgitta I Hiddinga, Jan P van Meerbeeck
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 27, 2010
The role of EBUS-TBNA for the assessment of Hilar lymph nodesKurt G Tournoy, Jan P van Meerbeeck
Lung Cancer (Amsterdam, Netherlands)|March 17, 2009
Stage IIIA-N2 NSCLC: a review of its treatment approaches and future developmentsJan P van Meerbeeck, Veerle F M Surmont
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 8, 2014
Strengths, weaknesses, and opportunities of diagnostic breathomics in pleural mesothelioma-a hypothesisKevin Lamote, Kristiaan Nackaerts, Jan P van Meerbeeck
European Respiratory Review : an Official Journal of the European Respiratory Society|November 18, 2021
Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysisEline Schillebeeckx, Jan P van Meerbeeck, Kevin Lamote
Critical Reviews in Oncology/Hematology|August 11, 2020
Volatile organic compounds in human matrices as lung cancer biomarkers: a systematic reviewEline Janssens, Jan P van Meerbeeck, Kevin Lamote
Annals of Translational Medicine|December 5, 2017
Treatment recommendations by clinicians in stage I non-small cell lung cancer: better work-up leads to less discussionJo Raskin, Annelies Janssens, Jan P Van Meerbeeck
Journal of Thoracic Disease|May 1, 2018
International trends in the clinical epidemiology of malignant pleural mesotheliomaRonald A M Damhuis, Jan P van Meerbeeck
The New England Journal of Medicine|January 11, 2013
Fibulin-3 as a biomarker for pleural mesotheliomaKevin Lamote, Paul Baas, Jan P van Meerbeeck
Pageof 19

Showing results (21-30 of 190) with videos related to

Sort By:
Pageof 19
Current Opinion in Oncology|February 3, 2007
Neoadjuvant chemotherapy in the treatment of nonsmall-cell lung cancerRebecca De Pauw, Jan P van Meerbeeck
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2013
Surgery in mesothelioma--where do we go after MARS?Birgitta I Hiddinga, Jan P van Meerbeeck
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 27, 2010
The role of EBUS-TBNA for the assessment of Hilar lymph nodesKurt G Tournoy, Jan P van Meerbeeck
Lung Cancer (Amsterdam, Netherlands)|March 17, 2009
Stage IIIA-N2 NSCLC: a review of its treatment approaches and future developmentsJan P van Meerbeeck, Veerle F M Surmont
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 8, 2014
Strengths, weaknesses, and opportunities of diagnostic breathomics in pleural mesothelioma-a hypothesisKevin Lamote, Kristiaan Nackaerts, Jan P van Meerbeeck
European Respiratory Review : an Official Journal of the European Respiratory Society|November 18, 2021
Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysisEline Schillebeeckx, Jan P van Meerbeeck, Kevin Lamote
Critical Reviews in Oncology/Hematology|August 11, 2020
Volatile organic compounds in human matrices as lung cancer biomarkers: a systematic reviewEline Janssens, Jan P van Meerbeeck, Kevin Lamote
Annals of Translational Medicine|December 5, 2017
Treatment recommendations by clinicians in stage I non-small cell lung cancer: better work-up leads to less discussionJo Raskin, Annelies Janssens, Jan P Van Meerbeeck
Journal of Thoracic Disease|May 1, 2018
International trends in the clinical epidemiology of malignant pleural mesotheliomaRonald A M Damhuis, Jan P van Meerbeeck
The New England Journal of Medicine|January 11, 2013
Fibulin-3 as a biomarker for pleural mesotheliomaKevin Lamote, Paul Baas, Jan P van Meerbeeck
Pageof 19